Chiron's Informed Solution
Chiron believes its technology for quantifying DNA and RNA positions it to create disease management packages for diagnosis, therapy and prophylaxis. Alliances, both to bring in new diagnostics and therapeutics as well as information components, arecrucial to Chiron's disease management goals. Ciba Corning, the largest piece of Chiron's $600 million diagnostics business, is expected to provide the marketing infrastructure and some of the systems skills required to make the vision a reality.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.